14:00 EST Alterity ‘never lost sight’ of interest in Parkinson’s disease, CEO says
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
- Alterity Therapeutics reports cash balance of A$54.46M as of September 30
- Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds
- Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating
- Alterity Therapeutics presents data from ATH434 Phase 2 trial